IQuity Research Unveils Potential $18 Billion in Health Plan Cost-Savings and Demonstrates Effectiveness of Identifying At-Risk Autoimmune Disease Patients

IQuity announced that the company was published in a peer-reviewed article in the Journal of Clinical Medicine. This work is one of the first comprehensive overviews of prevalence, clinical characteristics, challenges, and financial impacts of […]

IQuity announced that the company was published in a peer-reviewed article in the Journal of Clinical Medicine. This work is one of the first comprehensive overviews of prevalence, clinical characteristics, challenges, and financial impacts of autoimmune diseases and related disorders (multiple sclerosis, ulcerative colitis, Crohn’s disease and rheumatoid arthritis, irritable bowel syndrome and fibromyalgia syndrome). These six conditions alone affect approximately 60 million people at an estimated cost to diagnose and treat of $90B annually.

Read the Full Article

Categories:

Date Posted:

May 13, 2019

Share This:

IQuity builds first data analytics platform to help payers find and fix their addressable autoimmune disease risks
Illuminating an Invisible Epidemic: A Systematic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes

recent posts